Comprehensive regulatory support for companies licensing pharmaceutical products in or out, ensuring seamless marketing authorisation transfers and compliance across Europe and the United Kingdom. Pharmafile acts as a neutral regulatory facilitator during licensing transactions managing due diligence, documentation handover, authority approvals, and post-deal regulatory continuity without engaging in the commercial or legal negotiation of the deal. Whether you are in-licensing a product (acquiring rights and dossiers from another company) or out-licensing your product to a partner, we handle the end-to-end regulatory process so that no compliance obligations are overlooked. We focus on maintaining product lifecycle continuity (quality, safety, efficacy) throughout the transition, providing an inspection-ready framework that satisfies EMA, MHRA, and national agency requirements. The EMA’s post-authorisation procedural advice for users of the centralised procedure (EMEA-H-19984/03 Rev. 117) addresses questions from marketing-authorisation holders on transferring marketing authorisations and outlines the Agency’s position on issues typically addressed in discussions with MAHs in the post-authorisation phase. Our role is strictly on the regulatory and scientific front: conducting thorough regulatory due diligence, preparing all variation or new application filings, and coordinating with both parties’ technical teams to facilitate a smooth handover of responsibilities.
Licensing In & Out Facilitation Services – EU & UK Regulatory Partner
Who This Service Is For
This service is ideal for:
- Pharmaceutical Companies Licensing Products In: Firms that are in-licensing a medicine from another MAH (often to expand their portfolio or enter a new therapeutic area), who need expert help to integrate the incoming product into their regulatory portfolio. For example, a generic company acquiring marketing rights for a branded product in certain markets, or a biotech licensing in a late-stage asset for local development and commercialisation. We assist by assessing the dossier you receive, identifying any gaps or country-specific requirements, and handling the marketing authorisation transfer or new filings needed so you can start selling under your name without delay. This is especially valuable for small-to-mid-sized pharma companies that lack in-house regulatory capacity to onboard a licensed-in product’s documentation and obligations.
- Companies Licensing Products Out (Divesting or Partnering): MAHs that are out-licensing or divesting one of their products (or an entire portfolio) to a partner company, typically to refocus on core areas or monetise an asset. If you are transferring a marketing authorisation to the licensee (for example, via a marketing authorisation transfer through EMA for centrally authorised products or a Change of Ownership application to the MHRA in the UK), we manage the entire regulatory handover. Likewise, if you grant a partner rights in territories where you will no longer be the MAH, we prepare the necessary data packages and liaise with the receiving party’s regulatory team to ensure they obtain their own approvals efficiently. Our facilitation allows the outgoing company to remain compliant up to the handover date and the incoming company to be fully ready on Day 1 as the new MAH.
- Joint Ventures and Co-Marketing Agreements: Situations where two companies agree to share marketing of a product (common in co-marketing or co-promotion deals, or when splitting geographies). We help establish clear regulatory roles and documentation flows between the parties. For instance, if each company will hold separate national licences (one in EU, one in UK), we coordinate parallel submissions so that both authorisations align in their product information and approval timing. If one company remains the technical dossier owner and another is a licensee, we put in place procedures for ongoing change management and pharmacovigilance data exchange so that regulators see a unified front despite multiple MAHs.
- Life Science Investors and Tech-Transfer Offices: Entities such as venture-backed startups acquiring assets, or university tech-transfer offices out-licensing a drug candidate to industry. These players often require regulatory guidance to navigate the dossier transfer and initial filing process, since they may not have full regulatory departments. We provide advisory and hands-on support to ensure that when an asset moves from one sponsor to another, all the regulatory groundwork (IND/IMPD/CTA files, orphan designations, scientific advice history, etc.) is properly conveyed and used effectively by the new sponsor. This service ensures that valuable data is not lost in transition and that the new sponsor can pick up development or marketing with minimal duplication of effort.
(Note: We focus on the regulatory and compliance aspects of licensing deals. We do not conduct financial valuation, IP due diligence, or act as a business broker in finding licensing partners. However, we frequently collaborate with your legal, business development, and IP teams to cover the regulatory sections of term sheets and agreements, ensuring the contract terms about data provision, regulatory milestones, and responsibilities are clear and achievable).
Regulatory Challenges We Address
- Regulatory Due Diligence & Dossier Gaps: Licensing deals can falter if the dossier or compliance status of a product is not as advertised. A common challenge is unearthing hidden issues in the target product’s regulatory file outdated Module 3 data, missing study reports, unresolved variation commitments, or pharmacovigilance liabilities. We perform thorough regulatory due diligence on the product being licensed in or out: reviewing the CTD modules for completeness, checking health authority correspondence for any pending obligations or signals, and verifying that quality (GMP) and safety (GVP) compliance is up to date. By pinpointing these gaps early, we allow both parties to factor in remediation steps or adjust the deal scope, avoiding unpleasant surprises post-transaction.
- Marketing Authorisation Transfer Logistics: The mechanics of transferring a marketing authorisation from one holder to another involve multi-step regulatory procedures that can be tricky to time correctly. The EMA’s transfer guidance raises specific procedural questions that MAHs must address, including how to choose the implementation date, how to handle planned or ongoing variations procedures during the transfer, how to handle remaining post-authorisation measures and recommendations, whether mock-ups and specimens must be submitted, and whether changes to manufacturing sites or the product’s name can be included in the transfer application. In the UK, a Change of Ownership (COO) application to the MHRA is required for each licence. We develop a clear transfer plan: deciding the optimal window to submit the transfer so that it is approved in sync with deal closing, managing or pausing any ongoing variations so they do not conflict with the transfer, and preparing the required documents (new MAH proof of establishment, updated product information with new MAH name, proof of pharmacovigilance system, etc.).
- Data Ownership & Continuity of Regulatory Activities: Another challenge is ensuring the continuous fulfilment of regulatory obligations during and after the handover. This includes pharmacovigilance responsibilities, ongoing regulatory commitments, and manufacturing quality oversight. Regulators expect no lapse in these areas. The EMA guidance specifically addresses changing the qualified person for pharmacovigilance and what information on the summary of the transferee’s pharmacovigilance system should be submitted as part of a transfer application. It also addresses how to handle remaining post-authorisation measures and recommendations when transferring a marketing authorisation. We coordinate this continuity: helping the outgoing MAH share all safety data and pending periodic reports with the incoming MAH, and assisting the incoming MAH to set up their QPPV and register a summary of their PV system with authorities as part of the transfer.
- Multi-Jurisdictional Coordination: Licensing deals often span multiple regulatory jurisdictions. Each agency has its own processes and timelines. We handle the EU and UK aspects in parallel, making sure that an EMA transfer and MHRA transfer are aligned in effective date (so the new partner can launch under their name EU-wide at once, including Great Britain post-Brexit). The EMA’s procedural guidance notes that MAHs must comply with the requirements of Community legislation, and that provisions extend to Iceland, Liechtenstein and Norway by virtue of the European Economic Area agreement. We also provide data packages and regulatory affidavits needed by partners to tackle their local filings. Our involvement ensures a globally coherent strategy timing-wise and content-wise so that the product’s regulatory status remains stable internationally despite a change in ownership in certain regions.
- Legal Entity and Establishment Requirements: By law, a marketing authorisation holder must be established in the territory (EEA for EU authorisations, UK for UK authorisations). If a company is licensing a product to a foreign partner, that partner must have (or set up) an entity in the EEA/UK to hold the licence. We advise on and check this aspect early. We also navigate name and address changes: the new MAH’s details must be introduced via a variation to all product literature (SmPC, label, leaflet). The EMA’s guidance specifically addresses whether the name of a medicinal product can be changed as part of a transfer application. We ensure well before closing that the future MAH meets all eligibility criteria (establishment, GMP/GDP infrastructure, QPPV in place) so regulators will approve the transfer.
(Throughout our facilitation, we maintain strict confidentiality and neutrality. Both licensor and licensee can trust that proprietary data is handled securely and only shared as agreed in the licensing contract.)
What Regulators Expect
Regulatory authorities in the EU and UK expect that licensing transactions are carried out in a way that upholds the integrity of the product’s approval and oversight:
- Continuous MAH Responsibilities: Regulators insist that at no point does a product lack an accountable MAH. This means the original MAH must continue to fulfil all obligations (pharmacovigilance, product quality, supply continuity) until the date the new MAH legally takes over, and the new MAH must be fully ready on that date. A formal implementation date is agreed as part of the transfer procedure the EMA guidance addresses how to choose this implementation date as a discrete procedural question. In practice, we ensure that the outgoing QPPV continues to monitor safety up to the handover moment, after which the incoming QPPV (with a newly assigned PSMF for the product) takes charge seamlessly. Similarly, for ongoing manufacturing or testing, we often arrange for technical contracts to novate to the new MAH to maintain GMP oversight without interruption.
- Complete and Compliant Dossier Handover: When a licence is transferred or a product is in-licensed for a new application, the expectation is that the full regulatory dossier (Modules 1–5) is available to the new sponsor in an approvable state. The receiving company should have access to all data to answer any questions and maintain the licence. Regulators will not give leeway to a new MAH for missing information that the previous owner had; they will assume the new MAH has inherited all responsibilities along with the data. We facilitate a controlled transfer of the CTD: this might involve preparing a set of baseline submission files under the new MAH’s name (often via an “eCTD re-life” where we recompile the dossier for the new company’s submission system).
- Adherence to Transfer Procedures and Timetables: Authorities have defined procedures for transfers and they expect companies to follow the proper application routes and not attempt shortcuts. The EMA’s guidance should be read in conjunction with the rules governing medicinal products in the European Union, volume 2, notice to applicants. For centrally authorised products, EMA’s transfer guidance outlines what documentation is needed and how the application should be presented and submitted. For national licences via CMDh, similar requirements apply under national laws. Regulators do not want transfers to be used to bundle other unrelated changes the guidance addresses whether changes to manufacturing sites can be included in the transfer application as a separate question. We confirm our strategy with regulators if we need to combine certain variations (for efficiency) or keep them separate to avoid confusion.
- Pharmacovigilance System and QPPV in Place: One of the critical expectations during a transfer is that the transferee (new MAH) demonstrates an operational pharmacovigilance system from the first day of being MAH. The EMA guidance specifically asks what information on the summary of the transferee’s pharmacovigilance system should be submitted as part of the transfer application, and whether the qualified person for pharmacovigilance can be changed at the same time. Regulators will scrutinise this: they want to see that the new MAH either has its own robust PV system or has contracted one, and that the QPPV is registered and experienced. Any gap here can delay the transfer. We work with the new MAH to get all PV documentation ready for submission.
- Marketing authorisation holders should use the IRIS platform when managing transfers of marketing authorisation after the original submission. IRIS does not replace the current submission gateway; they coexist serving different functions. We ensure submissions are made through the appropriate channels and platforms.
- Manufacturing & Supply Chain Continuity: Another regulator focus is that the product’s quality and supply will not be negatively impacted by the change in MAH or licence conditions. The EMA guidance addresses whether changes to manufacturing sites can be included in the transfer application, reflecting that regulators want clarity on any supply chain changes coinciding with the ownership change. We reassure regulators by outlining any transitions: for instance, if artwork with the old company’s logo is in circulation, we commit to an agreed depletion timeline for packaging, with the new MAH ensuring that even packs with old details are covered by their pharmacovigilance and batch recall responsibility after the transfer.
- Orphan Designation Continuity: For products with orphan drug designations, the EMA guidance asks whether the orphan designation must also be transferred when transferring the marketing authorisation. We ensure that all related designations and entitlements are properly addressed in the transfer plan, so regulatory protections are maintained.
Our Licensing In & Out Facilitation Delivery Model
Our delivery model is structured to guide you through each phase of a licensing transaction on the regulatory side, from initial evaluation to post-handover support.
Regulatory Strategy for Licensing Transactions
Every licensing deal is unique, so we start by formulating a regulatory strategy aligned with your transaction objectives and timelines:
- Early Regulatory Input in Deal Planning: We engage at the due diligence or term-sheet stage to map out what regulatory steps will be required if the deal proceeds. This includes identifying which marketing authorisations need to be transferred or applications filed, estimating how long those will take, and flagging any major hurdles. We advise on the optimal effective date for transfer from a regulatory standpoint the EMA guidance addresses the question of how to choose the implementation date as a specific procedural consideration. By providing this foresight, we help structure deal clauses (for example, who will handle a planned variation that completes after transfer, or whether the transfer should wait until that variation is done to avoid confusion). We essentially create a regulatory project plan that dovetails with the business closing schedule, ensuring both sides know what will happen and when on the compliance front.
- Defining Roles and Responsibilities: As part of strategy, we outline exactly how responsibilities will shift and what interim arrangements might be needed. For a licensing-out, the companies might agree that the original MAH continues to manufacture for a transitional period under a CMO arrangement even after the MAH transfer. Or, the companies might agree that the new MAH will immediately take over pharmacovigilance reporting while the old MAH continues to assist for a defined period. We help document these plans in both the regulatory submission (so authorities see, for instance, that the Qualified Person for batch release will remain the same person at the same site, only now under contract to the new MAH) and in internal transition plans.
- Maintaining Product Value through Regulatory Compliance: Our strategy keeps the product’s regulatory value intact through the transition. This means planning to preserve all existing approvals and designations for instance, if the product has an orphan drug status, the EMA guidance asks whether an orphan designation must also be transferred when the marketing authorisation is transferred. We also strategies on branding continuity: the EMA guidance addresses whether a product name change can be effected as part of a transfer application, and we counsel whether a name change is advisable or necessary. By thinking through these details, our strategy ensures the product’s market presence and legal protections are as strong after the deal as before.
Regulatory Due Diligence & Gap Analysis
Before any handover of a licence or dossier, we perform a rigorous regulatory due diligence and gap analysis to identify any compliance or data issues:
- CTD Gap Analysis: Our regulatory experts (covering CMC, non-clinical, clinical, labelling, and PV) review the current dossier in detail. We check Module 3 for completeness against current guidelines for example, if the product was approved years ago, are there any updated stability or impurity requirements now expected by authorities? We examine Modules 4 and 5 to ensure all studies cited in labelling have reports available and that any specific local clinical data is included if needed for new markets. If the product is authorised in Europe but the licensee plans to seek approval in additional EU countries or the UK, we identify if bridging studies or updated clinical overviews may be necessary for those submissions. Any deficiency risks (say, a missing environmental risk assessment or an outdated Risk Management Plan) are catalogued. We then provide a report of these gaps with recommendations: which can be remedied easily (perhaps by compiling some additional data or doing a small lab validation) and which would require a longer-term plan.
- Compliance History and Commitments Audit: We scrutinise the product’s regulatory history to flag any outstanding commitments or past compliance concerns. This means reviewing lists of post-authorisation measures or specific obligations, inspecting Periodic Safety Update Report (PSUR) submissions and assessment reports to see if authorities had concerns, looking at any GMP compliance issues at manufacturing sites relevant to the product, etc. The EMA guidance specifically addresses how to handle remaining post-authorisation measures and recommendations when transferring a marketing authorisation we ensure the licensee is fully aware of and prepared to fulfil these inherited obligations.
- Risk Mitigation Plan: For each gap or issue identified, we develop a mitigation plan as part of the due diligence report. If critical studies are missing, perhaps the strategy is to commit to a specific post-transfer variation or study; if a manufacturing site lacks a renewal of GMP certificate, we schedule a re-inspection or plan to switch to an approved site as an urgent variation post-transfer. We prioritise which gaps must be resolved before transfer (any showstoppers for regulatory approval of the transfer itself) and which can be addressed right after transfer under the new MAH’s auspices. This becomes a regulatory “to-do list” that can be incorporated into transition planning.
Data Transfer, Ownership & Lifecycle Continuity
Transferring the actual regulatory data and ensuring lifecycle activities continue smoothly is a complex logistical task we manage end-to-end:
- Secure Data Handover: We organise the transfer of the CTD dossier and related files from the licensor to the licensee in a secure and systematic manner. We label and inventory every item: all volumes of the CTD (Module 1 country-specific documents, Modules 2–5), all regulatory correspondence letters, all historical variation approvals, inspection reports, PSURs, RMP documents, labelling history, and so on. We ensure the licensee receives the source files (not just PDFs) where available — for example, Word files of the Product Information to enable efficient future updates. As part of this, we often migrate the eCTD: if the product was in eCTD format with the original MAH, we help the new MAH to import it into their publishing system and continue the sequence numbering without break. This thoroughness positions the new MAH to operate day-to-day without missing files.
- Marketing Authorisation Transfer Application or New MA Submission: We prepare and submit the necessary regulatory applications to effect the licence change. For an EU centrally authorised product, the EMA guidance outlines how the application should be presented and how and to whom it should be submitted, with a defined timetable for handling the application. Marketing authorisation holders should use the IRIS platform when managing transfers of marketing authorisation after the original submission. For national licences, similar requirements apply under each country’s laws. For UK licences, we prepare the Change of Ownership application for the MHRA. In either case transfer or new submission we project-manage the timeline so that the regulatory approval of the change aligns with commercial expectations.
- Lifecycle Management During Transition: Maintaining the product’s lifecycle activities (like ongoing variations, renewals, and audits) is critical to regulators. We devise a plan for each ongoing or needed activity at the point of handover:
- If a renewal of the marketing authorisation is due soon and will occur around the transfer time, we decide who will file it. Often, the original MAH will commit to complete the renewal (since they have all historical data readily at hand) and then transfer the product, or if timing dictates the licensee will handle it, we assist them in preparation using the provided data.
- For ongoing variations, the EMA guidance specifically addresses how to handle planned or ongoing variations procedures during the transfer of marketing authorisation. We coordinate with the agency to determine the best approach sometimes the solution is to pause the variation until transfer is done, or to sequence the approvals so the new licence reflects all updates. We handle these technical adjustments so that nothing falls through the cracks.
- For pharmacovigilance data, we ensure a clean cut-over of responsibility on the effective date. We supervise the transfer of the safety database entries and make sure that delegated activities like literature monitoring or periodic report scheduling are updated with the new MAH’s details.
Authority Interactions, Variations & Timelines
Navigating communications with health authorities and managing regulatory procedures to effect the licensing handover is a core part of our role:
- Single Point of Contact with Agencies: We usually serve as the liaison with EMA, national authorities, and MHRA for all transfer-related matters. This relieves both the licensor and licensee from having to separately coordinate with agencies. For centrally authorised products, the EMA guidance provides contact details for questions during application preparation or during the procedure. We clarify any country-specific expectations (some NCAs require physical licence certificates to be returned, others require specific national forms). By consolidating these communications, we ensure a consistent and efficient approach.
- Managing Transfer Timetable and Related Variations: We actively manage the detailed timetable of the transfer across all jurisdictions. The EMA guidance addresses how the transfer application is handled, including a defined timetable, the applicable fee structure, and whether mock-ups and specimens must be submitted. We track each jurisdiction’s progress and give regular updates to both parties. In parallel, we prepare any necessary follow-up variations that need to be executed shortly after transfer: common ones include updating QPPV details and updating the Product Information with the new MAH’s details. The EMA guidance addresses QPPV changes as part of the transfer application itself.
- Addressing Regulatory Questions and Concerns: It is not uncommon for regulators to have concerns during a transfer, especially if the new MAH is less known to them or the product has particular issues. We address these confidently: providing written explanations or evidence. Our familiarity with the process and our professional rapport with many regulatory agencies means we can resolve queries quickly and keep the process on track.
- Final Regulatory Approvals and Notifications: Once the transfer or new licence is approved, we obtain the official documents and distribute copies to both parties. We then guide the new MAH in any final steps. The EMA guidance also addresses whether there will be any publication on the transfer of marketing authorisation. We ensure regulators see that the changeover has been fully executed as approved and that all stakeholders are kept in the loop as appropriate.
Post Deal Compliance & Ongoing Support (Optional)
After the licensing transaction is completed, we continue to support the new arrangement to ensure long-term regulatory compliance:
- MAH Compliance Training and SOP Updates: Often the new MAH (especially if they are a smaller company or entering a new market) benefits from training and procedural upgrades to handle their new responsibilities. We provide targeted training sessions on topics such as pharmacovigilance reporting requirements, how to manage variations and renewals for the product, and GMP/GDP expectations if they are now taking on distribution or batch release. This is particularly valuable if the new MAH has not marketed a product in the relevant region before; we essentially mentor their regulatory team through the first months.
- Regulatory Lifecycle Management: We remain available to manage upcoming lifecycle activities for the product on an ongoing basis. This could be under a retained services agreement where we act as the regulatory department for the product. For example, when it is time for the product’s next Periodic Safety Update Report, we can compile and submit it on behalf of the new MAH. If new variations are required (say, updating shelf life based on new stability data or implementing changes agreed in the deal), we prepare and file those. Essentially, we ensure that the product continues to be maintained to the highest regulatory standards under its new ownership.
- Bridge Between Old and New MAH Responsibilities: Even after transfer, there may be instances where cooperation between old and new MAH is needed. For example, if a quality defect or safety issue rooted in the pre-transfer period comes up, the investigation might involve both companies. We can act as a coordinator in such joint investigations, making sure the response to authorities is unified and comprehensive. By serving as an interface even post-transfer, we prevent anything from falling through the cracks during the period where the transition is fresh.
- Strategic Advisory for Further Developments: Sometimes after an in-licensing, the licensee (new MAH) plans further development of the product new indications, formulation improvements, or geographic expansion. Our team, already intimately familiar with the product’s dossier, continues as a strategic advisor or regulatory service provider for those initiatives. Our relationship can extend into a long-term partnership, where the licensing deal’s success is amplified by subsequent regulatory achievements all underpinned by the continuity and knowledge we carry from the licensing facilitation phase.
Jurisdictions Covered
Our Licensing Facilitation services cover transactions involving marketing authorisations in Europe, the United Kingdom, and related international contexts:
- European Union (Centralised, DCP/MRP, National): We handle licence transfers and in-/out-licensing support across all EU/EEA countries. The EMA’s procedural guidance notes that provisions extend to Iceland, Liechtenstein and Norway by virtue of the European Economic Area agreement. This includes centrally authorised products (where we liaise with EMA and the European Commission for transfers using the IRIS platform), as well as mutual recognition and decentralised licences (where coordination with multiple National Competent Authorities is required to effect a transfer in all concerned member states). We are familiar with specific national requirements in major markets and ensure EEA-wide compliance. For purely national licences, we execute the change per each country’s laws. Our pan-European reach means a company can engage us as a single partner to cover the whole EEA transfer, rather than dealing with separate agents in each country.
- United Kingdom (Post-Brexit UK & Northern Ireland): We cover licensing transactions involving UK licences, which since January 2021 follow the UK’s own procedures. We prepare Change of Ownership applications for Great Britain licences and coordinate with the MHRA to schedule the transfer. We also handle the necessary updates for Northern Ireland authorisations, which, under the Northern Ireland Protocol/Windsor Framework, continue to align with EU regulatory systems. We are adept at managing these dual regulatory regimes so that UK and EU compliance progresses in parallel without conflict. If the licensing deal involves moving products between a UK entity and an EU entity (common in post-Brexit portfolio reallocations), our knowledge of both regulatory frameworks ensures nothing is lost in translation.
- Other Regions (through Partnership): While our focus is on EU and UK authorisations, licensing deals often have global reach. We regularly interface with regulatory consultants or authorities in other jurisdictions to support our client. Through our network of international regulatory partners, we can extend the facilitation concept to virtually any market acting as a central hub to make sure the scientific and technical content stays consistent worldwide while each local regulatory requirement is met.
Typical Timelines
The timelines for regulatory steps in licensing transactions can vary depending on the complexity of the product and the number of jurisdictions. Below are indicative timelines for key activities under our facilitation (assuming both parties promptly provide required documents and approvals). Specific day-counts should be confirmed against current agency published guidance and internal records before publication.
| Activity | Typical Timeframe | Notes |
| Regulatory Due Diligence Report | 2–4 weeks | From the start of data access to delivery of our gap analysis. Complex products (biologicals, extensive data) tend toward 4 weeks. We often align this with the deal’s due diligence phase. |
| MRP/DCP Licence Transfer (all CMS) | Variable by country | Coordination via Reference Member State. Each NCA processes the transfer per national law. All transfers are ideally synchronised to one common effective date. |
| UK Change of Ownership | Variable | MHRA processes Change of Ownership applications under its own published timescales. |
| New National MA Application by Licensee (if needed) | 6–12 months to approval (estimated) | If a licence needs to be obtained by the licensee in a new country (not transfer of existing MA), timeline depends on the country’s review clock. |
| Data / Dossier Handover Completion | 1–2 months | After deal signing, assembling and transferring all files typically takes a few weeks. We often prioritise critical modules first (quality and PV data) and complete full archive transfer within 2 months. |
| Artwork & Packaging Changeover | 1–6 months (post-approval) | Depends on existing stock and market agreements. Regulators usually allow a sell-through period for old packaging. |
| Joint Update of PV/System | Concurrent with transfer | New QPPV and PSMF details must be notified in accordance with the applicable regulatory requirements. The EMA guidance addresses QPPV changes and PV system summary requirements as part of the transfer application |
| Post-Transfer Regulatory Actions (variations, renewals) | As per standard timelines | Variations to update administrative details — immediate or per standard timetable. Next renewal as scheduled (typically 5-year cycle). We pre-schedule these so none are missed. |
| Overall End-to-End Transaction Support | ~3–6 months (estimated) | From initial engagement (due diligence) through regulatory approvals to immediate post-transfer tasks. Shorter for simple single-country transfers; longer for multi-country or complex issues. Parts run in parallel. |
Note: These timelines assume no major unforeseen hurdles. We build contingency into plans. The earlier we are involved, the more precisely we can map regulatory timings to your transaction schedule.
Common Mistakes We Help You Avoid
Through extensive experience, we have identified a number of common pitfalls in licensing transactions that can lead to regulatory headaches or deal value erosion. Our services are designed to pre-empt these:
- Incomplete Handover of Documentation: A frequent issue is when the outgoing MAH fails to transfer some piece of the dossier or knowledge, and the incoming MAH only discovers this when regulators ask later. We prevent this by using comprehensive checklists during data transfer we reconcile the contents of the CTD with what has been received, and we insist on including files like raw study datasets, inspection reports, module 1 correspondence, etc. By ensuring the new MAH is not missing critical information, we avoid the scenario of telling an agency “we don’t have that data because it wasn’t given to us.”
- Poor Coordination Leading to Lapse in PV or Quality Oversight: Another common mistake is lack of clarity on who is covering pharmacovigilance or batch release at each moment. We have seen cases where, due to miscommunication, both the old and new QPPVs assumed the other was handling an alert, and thus a required safety report was not submitted. We establish crystal-clear responsibility matrices and often overlap coverage (for instance, during the first month post-transfer, we arrange that the old QPPV will continue to forward any reports to the new QPPV, and we keep a joint log so nothing is missed). We also formally notify agencies of the exact transfer date and contacts, so they know who to call.
- Rushing or Delaying Transfer Inappropriately: Timing is tricky some companies try to rush the transfer to meet a financial closing date, but they do so without aligning the regulatory pieces, leading to issues (for example, the transfer goes through but a major variation was still open). The EMA guidance addresses how to handle planned or ongoing variations procedures during the transfer precisely because this is a known risk. Others delay transfer too long because they fear the process, leading to an unnecessarily long period of dual effort. We avoid these mistakes by carefully calibrating timing: if speed is essential, we leverage expedited procedures where possible; if patience is wiser (for example, wait for an ongoing variation to conclude so the new MAH inherits an updated licence), we advise accordingly.
- Neglecting Local Regulatory Nuances: A common pitfall, especially in multi-country deals, is assuming the transfer rules are identical everywhere and thus skipping a requirement in a particular country. For example, not realising that in some countries a local agent or local QPPV appointment letter is needed at transfer, or forgetting to update the pharmaceutical product database in a country. We know these nuances or research them thoroughly as part of our planning. We treat each country’s requirements with equal care, preventing a “patchy” transfer where most EU countries approve but one or two lag due to an overlooked local rule.
- Changing Too Many Variables at Once: In the excitement of a new partnership, companies sometimes want to implement numerous changes simultaneously new branding, new manufacturing arrangements, formula tweaks, etc., on top of the MAH change. The EMA guidance addresses changes to manufacturing sites and product name changes as separate questions from the transfer itself, reflecting the importance of managing these distinctly. We counsel a phased approach: separate the MAH change from other major changes whenever feasible. For instance, do the MAH transfer first as its own variation, then a couple of months later, once that is settled, file the manufacturing site change or the product name change. This clear segmentation not only makes reviews smoother (agencies handle one focus at a time) but also isolates risk.
- Failing to Address Orphan Designations or Special Statuses: The EMA guidance explicitly raises the question of whether an orphan designation must also be transferred when the marketing authorisation is transferred. Companies sometimes overlook that related designations (orphan, paediatric exclusivity, etc.) may need separate procedural steps. We ensure that all regulatory protections associated with the product are properly managed through the transition.
Transferring a marketing authorisation (MA) means officially moving the product’s licence from the current Marketing Authorisation Holder to a new MAH. The EMA’s post-authorisation procedural guidance addresses questions from marketing-authorisation holders on transferring marketing authorisations and outlines the Agency’s position on issues typically discussed with MAHs. The new MAH must provide documentation including the transfer consent from the old MAH, proof of the new MAH’s establishment, details of the new pharmacovigilance system and QPPV, and updated product information with the new MAH’s name. The authority will review and, if all is in order, approve the transfer with a specified implementation date. From that date onward, the new MAH assumes all legal responsibilities for the product.
It is highly recommended. Regulatory due diligence is the process of reviewing the product’s regulatory compliance status and dossier completeness before finalising the deal. Even straightforward products can hide compliance issues an outstanding post-authorisation commitment, outdated manufacturing data, or pharmacovigilance liabilities. Our due diligence typically examines the CTD for gaps, checks variation history and whether all past regulatory commitments have been fulfilled, and assesses if the product meets current guidelines. This protects both parties: the licensee knows what they are getting, and the licensor discloses everything to avoid future disputes.
We create a detailed pharmacovigilance transition plan. This includes setting the effective date and time for PV responsibility shift (aligned with the MA transfer date). The EMA guidance specifically addresses the ability to change the qualified person for pharmacovigilance as part of the transfer, and what information on the transferee’s pharmacovigilance system should be submitted. We ensure all safety data (case histories, PSURs, signal analyses) is transferred to the new MAH’s safety database, that any open safety queries are jointly reviewed and a single owner appointed, that the new MAH has an operational PSMF that includes the product, and that the QPPV has been fully briefed on the product’s safety profile and history. We also overlap coverage as a safeguard for a few weeks around the cutover.
The EMA guidance addresses how to handle planned or ongoing variations procedures during the transfer of marketing authorisation as a specific procedural question. Handling ongoing variations during a transfer requires careful timing. Ideally, we try to complete or withdraw major variations before the transfer effective date. However, if one is unavoidably ongoing, there are mechanisms: the variation may be paused and the new MAH re-submits it after transfer, or the agencies may be asked to synchronise the variation approval with the transfer. We will coordinate with the authorities on a case-by-case plan. The key is communication we ensure regulators are informed about any ongoing variations as part of the transfer application.
Related Services & Resources
A successful licensing transaction draws on multiple regulatory disciplines we integrate our Licensing Facilitation service with several of our other offerings to provide a comprehensive solution:
- Regulatory Affairs Management: Our general RA services complement licensing support by handling the post-transfer lifecycle management. After we facilitate the transfer, our Regulatory Affairs team can take over routine management of the product: preparing upcoming variations, managing regular submissions and correspondence, and ensuring the new MAH’s regulatory obligations are continuously met. (See our Regulatory Affairs Management page for how we manage end-to-end lifecycle tasks.)
- Pharmacovigilance Services: Licensing in a product means inheriting its safety data and ongoing vigilance duties. Our Pharmacovigilance team often steps in to either set up the new MAH’s PV system or provide interim PV services during the transition (for example, serving as QPPV until the new company’s QPPV is fully established). We also offer to run the PSUR schedule or signal detection for the product on an ongoing basis. (Refer to Pharmacovigilance Services for details on QPPV provision and PV system outsourcing.)
- Quality & GMP Compliance: If the licensing deal involves tech transfer of manufacturing or adding new manufacturing sites for the new MAH, our Quality experts assist with GMP compliance, site variations, and audit coordination. We ensure that any contract manufacturing agreements are regulatory-compliant and that the new MAH obtains a Wholesale Dealer’s Licence or Manufacturing Licence if needed to distribute the product. (Our Quality Services page outlines support for GMP audits, QP services, and more.)
- Medical Writing & Dossier Publishing: In many licence deals, dossier publishing becomes an issue the outgoing company might have the eCTD sequences, and the incoming company needs to start their own. Our Medical Writing and Publishing service takes the dossier in whatever format (eCTD, NeeS, paper) and publishes it under the new MAH’s umbrella, ensuring continuity. We can also author any necessary bridging documents (like addenda to Clinical Overviews or new Module 2 summaries) if the new MAH has to file in a jurisdiction where the product was not previously approved. (See Medical Writing & eCTD services for how we handle dossier compilation and submissions.)
- Training & Advisory Workshops: For companies new to holding a marketing authorisation, we provide customised training workshops effectively a “Marketing Authorisation 101” for your staff covering regulatory obligations, how to handle inspections as a new MAH, etc. We can do this as part of the handover. (Our Knowledge Centre and Insights publish articles on licensing best practices.)
- Legal and IP Coordination: While we do not provide legal services, we frequently work alongside legal counsel to implement the regulatory aspects of what the licensing agreement spells out. Our familiarity with typical contract language in pharma licensing means we can proactively advise your lawyers if a proposed term might be unworkable regulatory-wise (for example, a clause specifying a transfer timeline that does not align with the agency’s published timetable). We aim for a frictionless collaboration between the deal team and the regulatory execution.
By combining these services, Pharmafile offers a comprehensive solution: we not only handle the immediate regulatory filings for licensing, but also set you up for long-term success with that product. Licensing a product is not just a one-time event it is the acquisition of a living asset that must be nurtured in the regulatory landscape. Through our integrated approach, we become that asset’s caretakers on your behalf, from the moment of deal conception to years into its growth under your wing.

